ATE152350T1 - Pharmazeutische zusammensetzungen die 5- difluormethoxy-2-(3,4-dimethoxy-2- pyridyl)methylsulfinyl>-1h-benzimidazol und ein anti-heliobactermittel enthalten zur behandlung von magen-darm krankheiten - Google Patents

Pharmazeutische zusammensetzungen die 5- difluormethoxy-2-(3,4-dimethoxy-2- pyridyl)methylsulfinyl>-1h-benzimidazol und ein anti-heliobactermittel enthalten zur behandlung von magen-darm krankheiten

Info

Publication number
ATE152350T1
ATE152350T1 AT91915307T AT91915307T ATE152350T1 AT E152350 T1 ATE152350 T1 AT E152350T1 AT 91915307 T AT91915307 T AT 91915307T AT 91915307 T AT91915307 T AT 91915307T AT E152350 T1 ATE152350 T1 AT E152350T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
benzimidazole
heliobacter
methylsulfinyl
difluoromethoxy
Prior art date
Application number
AT91915307T
Other languages
English (en)
Inventor
Michael E Parsons
Original Assignee
Byk Gulden Lomberg Chem Fab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10681166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE152350(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Byk Gulden Lomberg Chem Fab filed Critical Byk Gulden Lomberg Chem Fab
Application granted granted Critical
Publication of ATE152350T1 publication Critical patent/ATE152350T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
AT91915307T 1990-08-24 1991-08-23 Pharmazeutische zusammensetzungen die 5- difluormethoxy-2-(3,4-dimethoxy-2- pyridyl)methylsulfinyl>-1h-benzimidazol und ein anti-heliobactermittel enthalten zur behandlung von magen-darm krankheiten ATE152350T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909018603A GB9018603D0 (en) 1990-08-24 1990-08-24 Compositions

Publications (1)

Publication Number Publication Date
ATE152350T1 true ATE152350T1 (de) 1997-05-15

Family

ID=10681166

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91915307T ATE152350T1 (de) 1990-08-24 1991-08-23 Pharmazeutische zusammensetzungen die 5- difluormethoxy-2-(3,4-dimethoxy-2- pyridyl)methylsulfinyl>-1h-benzimidazol und ein anti-heliobactermittel enthalten zur behandlung von magen-darm krankheiten

Country Status (13)

Country Link
EP (1) EP0544760B1 (de)
JP (1) JPH06503806A (de)
KR (1) KR930701166A (de)
AT (1) ATE152350T1 (de)
AU (1) AU658831B2 (de)
CA (1) CA2089748C (de)
CY (1) CY2167B1 (de)
DE (1) DE69125940T2 (de)
DK (1) DK0544760T3 (de)
ES (1) ES2103825T3 (de)
GB (1) GB9018603D0 (de)
GR (1) GR3024058T3 (de)
WO (1) WO1992003135A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS3990A (is) * 1992-04-24 1993-10-25 Ab Astra Aðferð við að blanda saman efni sem hindrar flæðimagasýru og bakteríueyðandi efnis sem brotnar niður í súru umhverfi
EP0673246A1 (de) * 1992-12-10 1995-09-27 Byk Gulden Lomberg Chemische Fabrik GmbH Verwendung von alkylthiopyridinen zur bekämpfung von heliobacter-bakterien
WO1994027606A1 (en) * 1993-05-28 1994-12-08 Unisearch Limited Method of treating helicobacter pylori infection
ES2145102T3 (es) 1993-09-09 2000-07-01 Takeda Chemical Industries Ltd Formulacion que comprende una sustancia antibacteriana y una sustancia antiulcerosa.
TW420610B (en) * 1994-04-07 2001-02-01 Pfizer A pharmaceutical composition for treating a H. pylori infection or gastric or duodenal ulcers
US5861518A (en) * 1994-11-21 1999-01-19 Dekker; Koenraad A. Phthalide compounds and their production process
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US6303644B1 (en) * 1997-07-25 2001-10-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Proton pump inhibitor in therapeutic combination with antibacterial substances
WO2005074898A2 (en) * 2004-01-28 2005-08-18 Altana Pharma Ag Composition comprising (s) pantoprazole and an antibiotic for treating helicobacter pylori
EP2601947A1 (de) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Kombinationspräparat mit fester Dosierung zur Behandlung von Erkrankungen einhergehend mit Helicobacter pylori

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85472A (en) * 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
US5196205A (en) * 1987-10-12 1993-03-23 Borody Thomas J Method for treatment of gastro intestinal disorders
JP2694361B2 (ja) * 1989-02-09 1997-12-24 アストラ アクチエボラグ 抗菌剤

Also Published As

Publication number Publication date
DE69125940T2 (de) 1997-12-18
GB9018603D0 (en) 1990-10-10
AU8424091A (en) 1992-03-17
CA2089748A1 (en) 1992-02-25
WO1992003135A1 (en) 1992-03-05
CY2167B1 (en) 2002-08-23
GR3024058T3 (en) 1997-10-31
DE69125940D1 (de) 1997-06-05
ES2103825T3 (es) 1997-10-01
EP0544760A1 (de) 1993-06-09
AU658831B2 (en) 1995-05-04
EP0544760B1 (de) 1997-05-02
CA2089748C (en) 2005-07-05
DK0544760T3 (da) 1997-09-22
KR930701166A (ko) 1993-06-11
JPH06503806A (ja) 1994-04-28

Similar Documents

Publication Publication Date Title
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
ATE82121T1 (de) Arzneimittel fuer die therapeutische behandlung von alopezie.
ATE252901T1 (de) Arzneimittel zur behandlung von entzündlichen herzkrankheiten
ATE411026T1 (de) Mittel zur behandlung der alzheimer-krankheit
ATE114113T1 (de) Verwendung von droloxifen bei der behandlung von knochenerkrankungen.
ATE123943T1 (de) Mittel zur behandlung und vorbeugung von bauchentzündungen, die als wirkstoff zink-l- carnosin-salze oder -komplexe enthalten.
NO972391D0 (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
NO902800L (no) Fremgangsmaate for fremstilling av 11beta-aryl-4-oestrener.
DE68929388D1 (de) Aus Harn isolierte antikoagulierende Verbindung
DE69125940D1 (de) Pharmazeutische zusammensetzungen die 5-difluormethoxy-2-[3,4-dimethoxy-2-pyridyl)methylsulfinyl]-1h-benzimidazol und ein anti-heliobactermittel enthalten zur behandlung von magen-darm krankheiten
ATE124681T1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
DK0443848T3 (da) Nyt antiulcermiddel
DE68903059D1 (de) Strontiumsalz, verfahren zu dessen herstellung und arzneimittel, die es enthalten.
ATE5256T1 (de) Phenylpiperazinderivate von 1,3,4oxadiazolylphenolen, ihre herstellung und diese enthaltende therapeutische mittel.
DE69621786D1 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
DE68905076D1 (de) Pharmazeutische zusammensetzung fuer die behandlung von hautwunden.
DE68916651D1 (de) Heilmittel zur behandlung von toxoplasmose.
FI925546A7 (fi) Amidiliittyneitä pyridyylihappojohdannaisia leukotrieeniin liittyvien sairauksien hoitamiseksi
ID20165A (id) Penggunaan asam 2-(3,4-dimetoksisinamoil)aminobenzoat untuk pembuatan obat untuk pengobatan atau pencegahan restenosis
ATE106883T1 (de) Azelastin-embonat, verfahren zu seiner herstellung und pharmazeutische zubereitungen, die als wirkstoff azelastin-embonat enthalten.
ATE67931T1 (de) Butylhydroxyanisole zur behandlung von retrovirus-krankheiten.
DE68916443D1 (de) Arzneimittel zur behandlung von kryptosporidiose.
DK417889D0 (da) Anvendelse af 2-azabicyklo(2.2.2.)-carboxylsyrederivater til fremstilling af medicinske produkter til behandling af vaskulaere sygdomme
DE69104058D1 (de) N-[(2-thenoylmerkapto-3-methyl)-butanoyl]-homocysteinthiolacton, verfahren zu seiner herstellung und diese enthaltende pharmaceutische zusammensetzungen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEFA Change of the company name
EELA Cancelled due to lapse of time